Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Breast Cancer Population Screening Program Results in Early Detection and Reduced Treatment and Health Care Costs for Medicaid.

Homan SG, Yun S, Bouras A, Schmaltz C, Gwanfogbe P, Lucht J.

J Public Health Manag Pract. 2019 Oct 4. doi: 10.1097/PHH.0000000000001041. [Epub ahead of print]

PMID:
31592983
2.

Cutaneous tuberculosis in Rio de Janeiro, Brazil: description of a series of 75 cases.

Mann D, Sant'Anna FM, Schmaltz CAS, Rolla V, Freitas DFS, Lyra MR, Sampaio FMS, do Valle ACF, Lourenço MCS, Quintella LP, Teichner TC, Cavalcante SC, Galhardo MCG.

Int J Dermatol. 2019 Sep 25. doi: 10.1111/ijd.14617. [Epub ahead of print]

PMID:
31553059
3.

Changes in the NK Cell Repertoire Related to Initiation of TB Treatment and Onset of Immune Reconstitution Inflammatory Syndrome in TB/HIV Co-infected Patients in Rio de Janeiro, Brazil-ANRS 12274.

Giacoia-Gripp CBW, Cazote ADS, da Silva TP, Sant'Anna FM, Schmaltz CAS, Brum TS, de Matos JA, Silva J, Benjamin A, Pilotto JH, Rolla VC, Morgado MG, Scott-Algara D.

Front Immunol. 2019 Aug 13;10:1800. doi: 10.3389/fimmu.2019.01800. eCollection 2019.

4.

Randomized Controlled Trial of Primary Health Care Strategies for the Promotion of Leisure-Time Physical Activity Among Older Brazilians.

Novais FV, Simoes EJ, Schmaltz C, Ramos LR.

J Phys Act Health. 2019 Jul 17:1-9. doi: 10.1123/jpah.2017-0502. [Epub ahead of print]

PMID:
31310991
5.

Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil.

Demitto FO, Schmaltz CAS, Sant'Anna FM, Arriaga MB, Andrade BB, Rolla VC.

PLoS One. 2019 Jun 6;14(6):e0217014. doi: 10.1371/journal.pone.0217014. eCollection 2019.

6.

Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial.

Xavier MS, Trajman A, Schmaltz CAS, Sant'anna FM, Maia IR, Hadad DJ, do Brasil PEAA, Rolla V.

Biomed Res Int. 2018 Dec 25;2018:9231835. doi: 10.1155/2018/9231835. eCollection 2018.

7.

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?

Schmaltz CAS, Demitto FO, Sant'Anna FM, Rolla VC.

Mem Inst Oswaldo Cruz. 2019 Feb 11;114:e180420. doi: 10.1590/0074-02760180420.

8.

Ovarian Cancer Survival in Missouri, 1996-2014.

Yoshida Y, Schmaltz CL, Jackson-Thompson J, Simoes EJ.

Mo Med. 2018 Nov-Dec;115(6):542-547.

9.

Hip and Knee Section, Pathogen Factors: Proceedings of International Consensus on Orthopedic Infections.

Carijo JH, Courtney PM, Goswami K, Groff H, Kendoff D, Matos J, Sandiford NA, Scheper H, Schmaltz CAS, Shubnyakov I, Tan TL, Wouthuyzen-Bakker M.

J Arthroplasty. 2019 Feb;34(2S):S381-S386. doi: 10.1016/j.arth.2018.09.022. Epub 2018 Oct 19. No abstract available.

PMID:
30343968
10.

Cutaneous tuberculosis and HIV infection at a referral centre in Rio de Janeiro, Brazil.

Mann D, Sant'Anna FM, Schmaltz CAS, Freitas DFS, Rolla VC, Cavalcante SC, Gutierrez-Galhardo MC.

Mem Inst Oswaldo Cruz. 2018 Jul 26;113(9):e180184. doi: 10.1590/0074-02760180184.

11.

Improving Visualization of Female Breast Cancer Survival Estimates: Analysis Using Interactive Mapping Reports.

Ben Ramadan AA, Jackson-Thompson J, Schmaltz CL.

JMIR Public Health Surveill. 2018 May 3;4(2):e42. doi: 10.2196/publichealth.8163.

12.

Tuberculosis Treatment Outcomes and Factors Associated with Each of Them in a Cohort Followed Up between 2010 and 2014.

Cardoso MA, do Brasil PEAA, Schmaltz CAS, Sant'Anna FM, Rolla VC.

Biomed Res Int. 2017;2017:3974651. doi: 10.1155/2017/3974651. Epub 2017 Dec 28.

13.

Estimated and Interactively Visualized Female Breast Cancer Incidence Rates in Missouri Senate Districts: 2008-2012.

Ben Ramadan AA, Jackson-Thompson J, Schmaltz CL.

Online J Public Health Inform. 2017 Dec 30;9(3):e197. doi: 10.5210/ojphi.v9i3.8084. eCollection 2017.

14.

The impact of screening on cancer incidence and mortality in Missouri, USA, 2004-2013.

Yoshida Y, Schmaltz CL, Jackson-Thompson J, Simoes EJ.

Public Health. 2018 Jan;154:51-58. doi: 10.1016/j.puhe.2017.10.015. Epub 2017 Dec 1.

PMID:
29197686
15.

Risk factors for increased immune reconstitution in response to Mycobacterium tuberculosis antigens in tuberculosis HIV-infected, antiretroviral-naïve patients.

da Silva TP, Giacoia-Gripp CBW, Schmaltz CA, Sant'Anna FM, Saad MH, Matos JA, de Lima E Silva JCA, Rolla VC, Morgado MG.

BMC Infect Dis. 2017 Sep 6;17(1):606. doi: 10.1186/s12879-017-2700-6.

16.

Usability Assessment of the Missouri Cancer Registry's Published Interactive Mapping Reports: Round One.

Ben Ramadan AA, Jackson-Thompson J, Schmaltz CL.

JMIR Hum Factors. 2017 Aug 4;4(3):e19. doi: 10.2196/humanfactors.7899.

17.

Danger in the streets: exposures to bloodborne pathogens after community sharp injuries in Rio de Janeiro, Brazil.

Costa MD, Rapparini C, Schmaltz CAS, Tuyama M, Lauria LM, Saraceni V, Barroso PF.

Braz J Infect Dis. 2017 May - Jun;21(3):306-311. doi: 10.1016/j.bjid.2017.03.003. Epub 2017 Mar 29.

18.

Trend analysis and survival of primary gallbladder cancer in the United States: a 1973-2009 population-based study.

Rahman R, Simoes EJ, Schmaltz C, Jackson CS, Ibdah JA.

Cancer Med. 2017 Apr;6(4):874-880. doi: 10.1002/cam4.1044. Epub 2017 Mar 20.

19.

Effectiveness of a scaled up physical activity intervention in Brazil: A natural experiment.

Simões EJ, Hallal PC, Siqueira FV, Schmaltz C, Menor D, Malta DC, Duarte H, Hino AA, Mielke GI, Pratt M, Reis RS.

Prev Med. 2017 Oct;103S:S66-S72. doi: 10.1016/j.ypmed.2016.09.032. Epub 2016 Sep 28.

20.

Increased risk for colorectal cancer under age 50 in racial and ethnic minorities living in the United States.

Rahman R, Schmaltz C, Jackson CS, Simoes EJ, Jackson-Thompson J, Ibdah JA.

Cancer Med. 2015 Dec;4(12):1863-70. doi: 10.1002/cam4.560. Epub 2015 Oct 16.

21.

T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.

da Silva TP, Giacoia-Gripp CB, Schmaltz CA, Sant Anna FM, Rolla V, Morgado MG.

PLoS One. 2013 Jun 19;8(6):e66095. doi: 10.1371/journal.pone.0066095. Print 2013.

22.

Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART.

Schmaltz CA, Santoro-Lopes G, Lourenço MC, Morgado MG, Velasque Lde S, Rolla VC.

PLoS One. 2012;7(9):e45704. doi: 10.1371/journal.pone.0045704. Epub 2012 Sep 25.

23.

Thyroid hormones in the neonate: an overview of physiology and clinical correlation.

Schmaltz C.

Adv Neonatal Care. 2012 Aug;12(4):217-22. doi: 10.1097/ANC.0b013e3182609239. Review.

PMID:
22864001
24.

Optochiasmatic tuberculoma as the sole manifestation of late recurrent tuberculosis.

Lima MA, Aversa A, Maranhão-Filho P, Lima GA, Curi A, Schmaltz CA, Santanna FM.

Rev Inst Med Trop Sao Paulo. 2012 Aug;54(4):229-30.

25.

Predictors of tuberculosis treatment outcomes.

Orofino Rde L, Brasil PE, Trajman A, Schmaltz CA, Dalcolmo M, Rolla VC.

J Bras Pneumol. 2012 Jan-Feb;38(1):88-97. English, Portuguese.

26.

[Common mesentery presenting with left-sided perforated appendicitis].

Flesch J, Oswald P, Grebici M, Schmaltz C, Bruant P, Burguet JL.

J Radiol. 2010 Sep;91(9 Pt 1):915-6. French. No abstract available.

PMID:
20814382
27.

Effectiveness of highly active antiretroviral therapy (HAART) used concomitantly with rifampicin in patients with tuberculosis and AIDS.

Sant'Anna FM, Velasque L, Costa MJ, Schmaltz CA, Morgado MG, Lourenço MC, Grinsztejn B, Rolla VC.

Braz J Infect Dis. 2009 Oct;13(5):362-6. doi: 10.1590/S1413-86702009000500010.

PMID:
20428637
28.

Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil.

Schmaltz CA, Sant'Anna FM, Neves SC, Velasque Lde S, Lourenço MC, Morgado MG, Rolla VC, Lopes GS.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):623-8. doi: 10.1097/QAI.0b013e3181b31e56.

PMID:
19730270
29.

Hypotension and shock in the preterm neonate.

Schmaltz C.

Adv Neonatal Care. 2009 Aug;9(4):156-62. doi: 10.1097/ANC.0b013e3181a68b2b. Review.

PMID:
19696569
30.

A Brazilian experience in response to "optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis".

Schmaltz CA, Lopes GS, Rolla VC.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):340; author reply 341-2. doi: 10.1097/QAI.0b013e31819001d5. No abstract available.

PMID:
19242266
31.

Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation.

Alpdogan O, Muriglan SJ, Kappel BJ, Doubrovina E, Schmaltz C, Schiro R, Eng JM, Greenberg AS, Willis LM, Rotolo JA, O'Reilly RJ, van den Brink MR.

Transplantation. 2003 Jun 27;75(12):1977-83.

PMID:
12829897
32.

T cells require TRAIL for optimal graft-versus-tumor activity.

Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon JJ, van den Brink MR.

Nat Med. 2002 Dec;8(12):1433-7. Epub 2002 Nov 11.

PMID:
12426560
33.

Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation.

Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, Greenberg AS, Willis LM, Murphy GF, Crawford JM, van den Brink MR.

Blood. 2003 Mar 15;101(6):2440-5. Epub 2002 Nov 7.

PMID:
12424195
34.

Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.

Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, Halm JA, Rich BE, van den Brink MR.

Blood. 2001 Oct 1;98(7):2256-65.

PMID:
11568014
35.

Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.

Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, Ferrara JL, Burakoff SJ, van den Brink MR.

Blood. 2001 May 1;97(9):2886-95.

PMID:
11313285
36.

Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system.

Ding HF, McGill G, Rowan S, Schmaltz C, Shimamura A, Fisher DE.

J Biol Chem. 1998 Oct 23;273(43):28378-83.

37.

Regulation of proliferation-survival decisions during tumor cell hypoxia.

Schmaltz C, Hardenbergh PH, Wells A, Fisher DE.

Mol Cell Biol. 1998 May;18(5):2845-54.

38.

atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity.

Westphal CH, Rowan S, Schmaltz C, Elson A, Fisher DE, Leder P.

Nat Genet. 1997 Aug;16(4):397-401.

PMID:
9241281
39.

Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints.

Westphal CH, Schmaltz C, Rowan S, Elson A, Fisher DE, Leder P.

Cancer Res. 1997 May 1;57(9):1664-7.

40.

Pleuro-pulmonary blastoma: a case report and review of the literature.

Schmaltz C, Sauter S, Opitz O, Harms D, Kremens B, Lohner M, Metz K, Brandis M, Niemeyer C.

Med Pediatr Oncol. 1995 Dec;25(6):479-84. Review.

PMID:
7565313
41.

Mapping of a gene for familial juvenile nephronophthisis: refining the map and defining flanking markers on chromosome 2. APN Study Group.

Hildebrandt F, Singh-Sawhney I, Schnieders B, Centofante L, Omran H, Pohlmann A, Schmaltz C, Wedekind H, Schubotz C, Antignac C, et al.

Am J Hum Genet. 1993 Dec;53(6):1256-61.

Supplemental Content

Loading ...
Support Center